94 related articles for article (PubMed ID: 23777919)
21. Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer.
Otvos L; Kovalszky I; Riolfi M; Ferla R; Olah J; Sztodola A; Nama K; Molino A; Piubello Q; Wade JD; Surmacz E
Eur J Cancer; 2011 Jul; 47(10):1578-84. PubMed ID: 21353530
[TBL] [Abstract][Full Text] [Related]
22. [Establishment of a bioluminescent MDA-MB-231 cell line for in vivo imaging of human triple-negative breast cancer xenograft].
Wang K; Xie SM; He JJ; Ren Y; Xia HB; Zhang XW
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Nov; 31(11):1812-8. PubMed ID: 22126756
[TBL] [Abstract][Full Text] [Related]
23. Loading Lovastatin into Camptothecin-Floxuridine Conjugate Nanocapsules for Enhancing Anti-metastatic Efficacy of Cocktail Chemotherapy on Triple-negative Breast Cancer.
Zhang N; Liang X; Gao C; Chen M; Zhou Y; Krueger CJ; Bao G; Gong Z; Dai Z
ACS Appl Mater Interfaces; 2018 Sep; 10(35):29385-29397. PubMed ID: 30096224
[TBL] [Abstract][Full Text] [Related]
24. Orally administered endoxifen is a new therapeutic agent for breast cancer.
Ahmad A; Ali SM; Ahmad MU; Sheikh S; Ahmad I
Breast Cancer Res Treat; 2010 Jul; 122(2):579-84. PubMed ID: 20052538
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.
Basu GD; Pathangey LB; Tinder TL; Gendler SJ; Mukherjee P
Breast Cancer Res; 2005; 7(4):R422-35. PubMed ID: 15987447
[TBL] [Abstract][Full Text] [Related]
26. Carcinoembryonic antigen cell adhesion molecule 6 predicts breast cancer recurrence following adjuvant tamoxifen.
Maraqa L; Cummings M; Peter MB; Shaaban AM; Horgan K; Hanby AM; Speirs V
Clin Cancer Res; 2008 Jan; 14(2):405-11. PubMed ID: 18223215
[TBL] [Abstract][Full Text] [Related]
27. Fate of PLA and PCL-Based Polymeric Nanocarriers in Cellular and Animal Models of Triple-Negative Breast Cancer.
Sitia L; Ferrari R; Violatto MB; Talamini L; Dragoni L; Colombo C; Colombo L; Lupi M; Ubezio P; D'Incalci M; Morbidelli M; Salmona M; Moscatelli D; Bigini P
Biomacromolecules; 2016 Mar; 17(3):744-55. PubMed ID: 26791775
[TBL] [Abstract][Full Text] [Related]
28. Naringin inhibits growth potential of human triple-negative breast cancer cells by targeting β-catenin signaling pathway.
Li H; Yang B; Huang J; Xiang T; Yin X; Wan J; Luo F; Zhang L; Li H; Ren G
Toxicol Lett; 2013 Jul; 220(3):219-28. PubMed ID: 23694763
[TBL] [Abstract][Full Text] [Related]
29. Tamoxifen citrate loaded chitosan-gellan nanocapsules for breast cancer therapy: development, characterisation and in-vitro cell viability study.
Kathle PK; Gautam N; Kesavan K
J Microencapsul; 2018 May; 35(3):292-300. PubMed ID: 29771175
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen.
Rouanet P; Linares-Cruz G; Dravet F; Poujol S; Gourgou S; Simony-Lafontaine J; Grenier J; Kramar A; Girault J; Le Nestour E; Maudelonde T
J Clin Oncol; 2005 May; 23(13):2980-7. PubMed ID: 15860853
[TBL] [Abstract][Full Text] [Related]
31. Tamoxifen and genistein synergistically down-regulate signal transduction and proliferation in estrogen receptor-negative human breast carcinoma MDA-MB-435 cells.
Shen F; Xue X; Weber G
Anticancer Res; 1999; 19(3A):1657-62. PubMed ID: 10470097
[TBL] [Abstract][Full Text] [Related]
32. Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124].
Seitz S; Buchholz S; Schally AV; Jayakumar AR; Weber F; Papadia A; Rick FG; Szalontay L; Treszl A; Köster F; Ortmann O; Hohla F
Anticancer Drugs; 2013 Feb; 24(2):150-7. PubMed ID: 23080077
[TBL] [Abstract][Full Text] [Related]
33. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
Kim EM; Mueller K; Gartner E; Boerner J
J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
[TBL] [Abstract][Full Text] [Related]
34. Agonists and antagonists of GnRH-I and -II reduce metastasis formation by triple-negative human breast cancer cells in vivo.
Schubert A; Hawighorst T; Emons G; Gründker C
Breast Cancer Res Treat; 2011 Dec; 130(3):783-90. PubMed ID: 21279682
[TBL] [Abstract][Full Text] [Related]
35. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
[TBL] [Abstract][Full Text] [Related]
36. Ferrociphenol lipid nanocapsule delivery by mesenchymal stromal cells in brain tumor therapy.
Roger M; Clavreul A; Huynh NT; Passirani C; Schiller P; Vessières A; Montero-Menei C; Menei P
Int J Pharm; 2012 Feb; 423(1):63-8. PubMed ID: 21554935
[TBL] [Abstract][Full Text] [Related]
37. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
[TBL] [Abstract][Full Text] [Related]
38. Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo.
Chattopadhyay M; Kodela R; Nath N; Barsegian A; Boring D; Kashfi K
Biochem Pharmacol; 2012 Mar; 83(6):723-32. PubMed ID: 22209867
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of cell survival, cell cycle progression, tumor growth and cyclooxygenase-2 activity in MDA-MB-231 breast cancer cells by camphorataimide B.
Lin WL; Lee YJ; Wang SM; Huang PY; Tseng TH
Eur J Pharmacol; 2012 Apr; 680(1-3):8-15. PubMed ID: 22329896
[TBL] [Abstract][Full Text] [Related]
40. Combinatorial Cytotoxic Effects of 2,3-Dichloro-5,8-dimethoxy-1,4-naphthoquinone and 4-hydroxytamoxifen in Triple-negative Breast Cancer Cell Lines.
Robinson AGJ; Kanaan YM; Copeland RL
Anticancer Res; 2020 Dec; 40(12):6623-6635. PubMed ID: 33288557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
